Argenx (ARGX) announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended European Commission approval of Vyvgart 1000mg for subcutaneous injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy after prior treatment with corticosteroids or immunoglobulins.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Se’s Revenue Growth Potential Boosted by Vyvgart Hytrulo’s Market Impact and Increased Treatment Cycles
- Argenx price target lowered to EUR 680 from EUR 736 at BofA
- Argenx price target raised to $796 from $681 at Citi
- Argenx Se’s Growth Potential Bolstered by Vyvgart Hytrulo Approval and Strategic Positioning
- Vyvgart for self-administration ‘immaterial’ to Option Care, says JPMorgan